Short answer
Voyager Therapeutics, Inc. (VYGR) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $3M (down 39.1% year over year) with net income of −$24M.
Q2 2026 key financials · XBRL
- Revenue
- $3M
- −39.1% YoY · +22.1% QoQ
- Net income
- −$24M
- +26.7% YoY · +12.4% QoQ
- Operating margin
- -833.9%
- EPS (diluted)
- −$0.40
- +29.8% YoY · +14.9% QoQ
Source: XBRL data from the Voyager Therapeutics, Inc. (VYGR) Q2 2026 10-Q on SEC EDGAR. USD.
Voyager Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New clinical-development risk triggered by FDA IND clearance: VY1706 trial expected to enroll up to 18 patients beginning fourth quarter 2026
- Materially updated collaboration risk: Novartis partial termination ended milestone and royalty eligibility for two programs effective February 1, 2026
- Regulatory risk from first-in-human VY1706 testing: clinical trial includes dose escalation up to 5 × 10^13 vector genomes per kilogram
- Operational risk from limited clinical-stage pipeline: VY1706 dosing expected fourth quarter 2026, with initial safety data anticipated early 2027
- Financial risk from continued funding needs: six-month net loss $52.4 million and accumulated deficit $498.3 million at June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Voyager Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.